09:25 AM EDT, 06/30/2025 (MT Newswires) -- Tyra Biosciences ( TYRA ) said Monday the first patient has been dosed in a phase 2 study of TYRA-300 in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Patients will receive once-daily doses of TYRA-300, with the primary endpoint being complete response at three months. Secondary endpoints include time to recurrence, the median duration of response, recurrence free survival, progression free survival, safety and tolerability.

The company expects initial response data in the H1 2026.

Tyra shares were 3.9% higher in premarket trading.